Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT03817502
Other study ID # RGH-MD-20
Secondary ID 2018-004006-26
Status Recruiting
Phase Phase 3
First received
Last updated
Start date June 6, 2019
Est. completion date April 1, 2025

Study information

Verified date February 2022
Source Gedeon Richter Plc.
Contact Balázs Lázár
Phone +36 1 432 6437
Email RA.ctaRichter@richter.hu
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the efficacy and safety of cariprazine in the treatment of schizophrenia in the adolescent population.


Recruitment information / eligibility

Status Recruiting
Enrollment 330
Est. completion date April 1, 2025
Est. primary completion date April 1, 2025
Accepts healthy volunteers No
Gender All
Age group 13 Years to 17 Years
Eligibility Inclusion Criteria: - DSM-5 primary diagnosis of schizophrenia. - Schizophrenia diagnosis confirmed by the K-SADS-PL administered at screening (Visit 1) by a trained clinician. - PANSS score = 70 and a score of = 4 (moderate) on 2 or more of the 5 items on the positive subscale of the PANSS (delusions, conceptual disorganization, hallucinatory behavior, grandiosity, suspiciousness/persecution), at screening (Visit 1) and baseline (Visit 2). - CGI-S scale score of = 4 (moderately ill) at screening (Visit 1) and baseline (Visit 2). Exclusion Criteria: - Current diagnosis of bipolar disorder, schizoaffective disorder, schizophreniform disorder, brief psychotic disorder, or psychotic disorder due to another medical condition - Diagnosis of intellectual disability (IQ < 70). - Participant has a history of meeting DSM-5 diagnosis for any substance-related disorder (except caffeine- and tobacco-related) within the 3 months before Visit 1.

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
Cariprazine
Cariprazine capsules, oral administration, once daily.
Placebo
Matching placebo capsules, oral administration, once daily.

Locations

Country Name City State
Bulgaria Clinic of Child Psychiatry St. Nikolas Sofia
Bulgaria MHAT Targovishte Targovishte
Colombia Centro de Investigaciones y Proyectos en Nerurociencia. CIPNA. IPS. SAS. Barranquilla
Colombia E.S.E. Hospital Mental de Antioquia Bello
Colombia Centro de Investigacion del Sitema Nervioso CISNE Bogotá
Colombia Instituto Colombiano Sistema Nervioso Clinica Monserrat Bogotá
Colombia Psynapsis Salud Mental SA Pereira
Mexico Centro para la Medicina y de Asistencia Medica Especializada S.C. Culiacán
Mexico Instituto de Investigacion Clinica AC Durango
Mexico Consultorio de Medicina Especializada del Sector Privado Guadalajara
Mexico Consultorio Medico En Psiquiatria de Niños y Adolescentes Hospital Aranda de la Parra Guanajuato
Mexico Medical Care and Research S.A. de C.V. Mérida
Mexico CIT Neuropsique Monterrey
Mexico Iecsi S.C. Monterrey
Mexico Instituto de Informacion e Investigacion en Salud Mental AC Monterrey
Mexico BLIND Investigaciones SC San Luis Potosí
Romania Socola Psychiatric Institute Iasi Iasi
Romania Spitalul Clinic de Urgenta Pentru Copii Louis Turcanu Clinica de Psihiatrie Copii Si Adolescenti Timisoara
Russian Federation State Institution of Healthcare "Arkhangelsk Regional Clinical Psychiatric Hospital" Arkhangel'sk
Russian Federation Kazan State Medical University KSMU Kazan
Russian Federation SBHI Specialized Clinical Psychiatric Hospital 1 Krasnodar
Russian Federation Regional Public Institution "Lipetsk Regional Psychoneurological Hospital" Lipetsk
Russian Federation Joint-Stock Company Scientific Centre of Personalized Medicine Moscow
Russian Federation SBHI of Moscow Region "Central Clinical Psychiatric Hospital" Moscow
Russian Federation Clinical Psychiatry Hospital #1 of Nizhniy Novgorod Nizhny Novgorod
Russian Federation State Public Institution of Healthcare Leningrad Regional Psychoneurological Dispensary Roshchino
Russian Federation City Psychiatric Hospital #3 after I.I. Skvortsova-Stepanova Saint Petersburg
Russian Federation Federal State Budgetary Institution "National Medical Research Center of Psychiatry and Neurology n.a. V.M. Bekhterev" of the Ministry of Healthcare of the Russian Federation Saint Petersburg
Russian Federation Saint-Petersburg GUZ Psychiatric Hospital No.1 n.a. P.P. Kaschenko Saint Petersburg
Russian Federation Center for Medical Rehabilitation named after S.S. Mnukhin Saint-Petersburg
Russian Federation GBUZ Samara Regional Clinical Psychiatric Hospital Samara
Russian Federation State Budgetary Healthcare Institution "Saratov City Clinical Hospital #2 n.a. V.I. Razumovsky" Saratov
Russian Federation Smolensk State Medical University Smolensk
Russian Federation LLC Podderzhka Stavropol
Russian Federation LLC Clinic "Sto Let" Tomsk
Russian Federation Stavropol Regional Psychiatric hospital #2 Tonnel'nyy
Russian Federation Yaroslavl Regional Psychiatric Hospital Yaroslavl Region
Serbia Clinic.Neuro.Psych.Child.Youth Belgrad
Serbia Institute for Mental Health Belgrad
Serbia Clinic for psychiatry, KCV Novi Sad
Ukraine Regional Psychonevrological Hospital #3 Ivano-Frankivsk
Ukraine SI "Institution of Neurology, Psychiatry and Narcology NAMS of Ukraine" Kharkiv
Ukraine State Institution "Institute of Health Care for Children and Adolescents of the AMS of Ukraine Kharkov
Ukraine Kherson Regional Institution of Mental Care Kherson
Ukraine SI Research Institute of Psychiatry of MoH of Ukraine Kyiv
Ukraine Communal Institution of Lviv Regional Council Lviv Regional Clinical Psychiatric Hospital Lviv
Ukraine Odesa Regional Medical Centre of Mental Health Odesa
Ukraine Municipal Institution "Vinnytsya Regional Psychoneurological Hospital n.a. Acad. O.I. Yushchenko" Vinnytsia
United States Atlanta Behavioral Research, LLC Atlanta Georgia
United States Atlanta Center for Medical Research Atlanta Georgia
United States Bloomfield Hills MI Bloomfield Hills Michigan
United States UB Department of Psychiatry Buffalo New York
United States University of Cincinnati Cincinnati Ohio
United States ProScience Research Group Culver City California
United States Precise Research Centers Flowood Mississippi
United States Manhattan Behavioral Medicine PLLC New York New York
United States Family Psychiatry of The Woodlands The Woodlands Texas

Sponsors (1)

Lead Sponsor Collaborator
Gedeon Richter Plc.

Countries where clinical trial is conducted

United States,  Bulgaria,  Colombia,  Mexico,  Romania,  Russian Federation,  Serbia,  Ukraine, 

Outcome

Type Measure Description Time frame Safety issue
Primary Change from baseline in PANSS total score at Week 6 The Positive and Negative Syndrome Scale is a 30-item rating scale specifically developed to asses both the positive and negative symptom syndromes of patients with schizophrenia. The PANSS total score is rated based on a structured clinical interview with the patient and supporting clinical information obtained from family, hospital staff, or other reliable informants. This assessment provides scores in 9 clinical domains, including a positive syndrome, a negative syndrome, depression, a composite index, and general psychopathology. Each item is scored on a 7-point (1 to 7) scale, with 1 being minimal impact, and 7 being highest impact. The cumulative score ranges from 30 to 210. A negative change from baseline score indicates improvement. Baseline to Week 6
See also
  Status Clinical Trial Phase
Recruiting NCT05039489 - A Study on the Brain Mechanism of cTBS in Improving Medication-resistant Auditory Hallucinations in Schizophrenia N/A
Completed NCT05111548 - Brain Stimulation and Cognitive Training - Efficacy N/A
Completed NCT05321602 - Study to Evaluate the PK Profiles of LY03010 in Patients With Schizophrenia or Schizoaffective Disorder Phase 1
Completed NCT04503954 - Efficacy of Chronic Disease Self-management Program in People With Schizophrenia N/A
Completed NCT02831231 - Pilot Study Comparing Effects of Xanomeline Alone to Xanomeline Plus Trospium Phase 1
Completed NCT05517460 - The Efficacy of Auricular Acupressure on Improving Constipation Among Residents in Community Rehabilitation Center N/A
Completed NCT03652974 - Disturbance of Plasma Cytokine Parameters in Clozapine-Resistant Treatment-Refractory Schizophrenia (CTRS) and Their Association With Combination Therapy Phase 4
Recruiting NCT04012684 - rTMS on Mismatch Negativity of Schizophrenia N/A
Recruiting NCT04481217 - Cognitive Factors Mediating the Relationship Between Childhood Trauma and Auditory Hallucinations in Schizophrenia N/A
Completed NCT00212784 - Efficacy and Safety of Asenapine Using an Active Control in Subjects With Schizophrenia or Schizoaffective Disorder (25517)(P05935) Phase 3
Completed NCT04092686 - A Clinical Trial That Will Study the Efficacy and Safety of an Investigational Drug in Acutely Psychotic People With Schizophrenia Phase 3
Completed NCT01914393 - Pediatric Open-Label Extension Study Phase 3
Recruiting NCT03790345 - Vitamin B6 and B12 in the Treatment of Movement Disorders Induced by Antipsychotics Phase 2/Phase 3
Recruiting NCT05956327 - Insight Into Hippocampal Neuroplasticity in Schizophrenia by Investigating Molecular Pathways During Physical Training N/A
Terminated NCT03261817 - A Controlled Study With Remote Web-based Adapted Physical Activity (e-APA) in Psychotic Disorders N/A
Terminated NCT03209778 - Involuntary Memories Investigation in Schizophrenia N/A
Completed NCT02905604 - Magnetic Stimulation of the Brain in Schizophrenia or Depression N/A
Recruiting NCT05542212 - Intra-cortical Inhibition and Cognitive Deficits in Schizophrenia N/A
Completed NCT04411979 - Effects of 12 Weeks Walking on Cognitive Function in Schizophrenia N/A
Terminated NCT03220438 - TMS Enhancement of Visual Plasticity in Schizophrenia N/A